Conference Coverage
Conference Coverage
Beyond semaglutide, a coming pipeline of new antiobesity meds
With the two highest doses of retatrutide, 100% of participants lost ≥ 5% of weight. “I’m not sure how many other times I will ever be able to say...
Conference Coverage
SGLT2 inhibitors in type 2 diabetes linked to lower risk of developing GI cancers
The study is notable for including people with ulcerative colitis and Crohn’s disease and for evaluating every GI cancer.
Conference Coverage
Tricyclics may raise fracture risk in type 2 diabetes
Although the findings are suggestive, they don’t definitively pin blame on tricyclic antidepressants alone in directly leading to fractures.
Conference Coverage
Common meds link to sudden cardiac arrest in type 2 diabetes
“If the patient has type 2 diabetes, then maybe it’s better to avoid some of these medications and try and cope without them, or at least find an...
Conference Coverage
Higher fracture risk not seen with SGLT2 inhibitors
Increased fracture risk seen in short-term studies may have been caused by hypovolemia or osmotic diuresis, resulting in falls, rather than an...
Conference Coverage
Antidepressants ‘don’t blunt’ semaglutide and weight loss
“Semaglutide 2.4 mg provides an effective treatment option for weight management, regardless of antidepressant use at baseline.”
Conference Coverage
New hyperglycemia emergency guidance updates DKA definition
New to the 2023 version will be a strong emphasis on the excess morbidity and mortality risks associated with the increasingly common “hybrid”...
Conference Coverage
Respiratory infections, asthma rise before type 2 diabetes
Taken together, the data suggest that subacute inflammation manifesting in asthma as well as the onset of asthma or an acute infection may be a...
Conference Coverage
Precision medicine takes individual approach to diabetes
“Because diabetes is an incredibly heterogeneous disease, few people are Mr. or Mrs. ‘average’ and one-size-fits-all approaches fail many people...
Conference Coverage
Weight loss with semaglutide maintained for up to 3 years
“Importantly, these effects were sustained for up to 3 years, supporting the use of once weekly semaglutide for the long-term management of type 2...